Bellicum Pharmaceuticals Inc

NASDAQ:BLCM   3:41:54 PM EDT
2.99
-0.15 (-4.78%)
Products, Regulatory

Bellicum Reports Clinical Hold Placed On BPX-601 Phase 1/2 Clinical Trial

Published: 12/07/2020 12:42 GMT
Bellicum Pharmaceuticals Inc (BLCM) - Bellicum Reports Clinical Hold Placed on Bpx-601 Phase 1/2 Clinical Trial.
Bellicum Pharmaceuticals Inc - FDA is Taking This Action Due to Death of a Pancreatic Cancer Patient in Trial Reported to Agency by Company.
Bellicum Pharmaceuticals Inc - Clinical Investigator and Bellicum Classified Patient Death As Unrelated to Bpx-601 and Rimiducid.
Bellicum Pharmaceuticals Inc - Plans to Work With FDA to Address Agency's Questions and Fulfill Requirements for Resuming Trial.
Bellicum Pharmaceuticals Inc - Clinical Hold Does Not Affect Company's Plans to Initiate Enrollment in Phase 1/2 Clinical Trial of Bpx-603.